The planning and design of a new PET radiochemistry facility

Mark S. Jacobson, Joseph C. Hung, Trenton L. Mays, Brian P. Mullan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The objectives of the Mayo positron emission tomography (PET) radiochemistry facility are the production of PET drugs for clinical service of our in-house patients, commercial distribution of PET drug products, and development of new PET drugs. The factors foremost in the planning and design phases were the current regulatory climate for PET drug production, radiation safety issues, and effective production flow. A medium-energy cyclotron was preferred for its small footprint to allow a compact vault, its high-proton energy to offer a higher product radioactivity; and its research capabilities. A vault installation was chosen instead of a self-shielded machine for improved access and ease of maintenance. Adjacent to the cyclotron is an area that houses the support equipment and a large dedicated workshop to support machine maintenance and targetry development. The total floor area of the PET radiochemistry facility is 344.2 m2 (3,705.5 ft2), of which the radiochemistry laboratory occupies 130.7 m2 (1,407 ft2). To reduce environmental contamination of PET drug products, the laboratory contains a controlled-air environment class 10,000 (M5.5) clean room with access via an interlocking entry change area. A fully shielded isolator (class 100 [M3.5]) is located in the clean room. The PET drugs are delivered via shielded tubing between the synthesizer and isolator. Inside the isolator, there is an automated device for dispensing the PET drug into either a bulk-activity vial or a unit-dose syringe. The dispensed PET radiopharmaceutical then passes through a hatch to a dedicated area where it is packaged for in-house use or commercial distribution. Unit doses for in-house patients are transported via pneumatic tube to the PET imaging area 76.2 m (250 ft) away. There is extensive radiation area monitoring throughout the facility that continuously measures radiation levels. We believe that our new PET radiochemistry facility not only meets overall objectives, but also provides an ergonomic, efficient working environment for the production and development of PET drugs.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalMolecular Imaging and Biology
Volume4
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Radiochemistry
Positron-Emission Tomography
Controlled Environment
Pharmaceutical Preparations
Cyclotrons
Radiation Monitoring
Maintenance
Radiation
Equipment and Supplies
Radiopharmaceuticals
Human Engineering
Syringes

Keywords

  • Controlled environment
  • Cyclotron
  • FDA guidelines
  • Hot cells
  • Isolator
  • Positron emission tomography PET
  • Production flow
  • Radiation safety
  • Self-shielded
  • Vault

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

The planning and design of a new PET radiochemistry facility. / Jacobson, Mark S.; Hung, Joseph C.; Mays, Trenton L.; Mullan, Brian P.

In: Molecular Imaging and Biology, Vol. 4, No. 2, 2002, p. 119-127.

Research output: Contribution to journalArticle

Jacobson, Mark S. ; Hung, Joseph C. ; Mays, Trenton L. ; Mullan, Brian P. / The planning and design of a new PET radiochemistry facility. In: Molecular Imaging and Biology. 2002 ; Vol. 4, No. 2. pp. 119-127.
@article{0bdcde8e8fd549cb948e1f4eb234b720,
title = "The planning and design of a new PET radiochemistry facility",
abstract = "The objectives of the Mayo positron emission tomography (PET) radiochemistry facility are the production of PET drugs for clinical service of our in-house patients, commercial distribution of PET drug products, and development of new PET drugs. The factors foremost in the planning and design phases were the current regulatory climate for PET drug production, radiation safety issues, and effective production flow. A medium-energy cyclotron was preferred for its small footprint to allow a compact vault, its high-proton energy to offer a higher product radioactivity; and its research capabilities. A vault installation was chosen instead of a self-shielded machine for improved access and ease of maintenance. Adjacent to the cyclotron is an area that houses the support equipment and a large dedicated workshop to support machine maintenance and targetry development. The total floor area of the PET radiochemistry facility is 344.2 m2 (3,705.5 ft2), of which the radiochemistry laboratory occupies 130.7 m2 (1,407 ft2). To reduce environmental contamination of PET drug products, the laboratory contains a controlled-air environment class 10,000 (M5.5) clean room with access via an interlocking entry change area. A fully shielded isolator (class 100 [M3.5]) is located in the clean room. The PET drugs are delivered via shielded tubing between the synthesizer and isolator. Inside the isolator, there is an automated device for dispensing the PET drug into either a bulk-activity vial or a unit-dose syringe. The dispensed PET radiopharmaceutical then passes through a hatch to a dedicated area where it is packaged for in-house use or commercial distribution. Unit doses for in-house patients are transported via pneumatic tube to the PET imaging area 76.2 m (250 ft) away. There is extensive radiation area monitoring throughout the facility that continuously measures radiation levels. We believe that our new PET radiochemistry facility not only meets overall objectives, but also provides an ergonomic, efficient working environment for the production and development of PET drugs.",
keywords = "Controlled environment, Cyclotron, FDA guidelines, Hot cells, Isolator, Positron emission tomography PET, Production flow, Radiation safety, Self-shielded, Vault",
author = "Jacobson, {Mark S.} and Hung, {Joseph C.} and Mays, {Trenton L.} and Mullan, {Brian P.}",
year = "2002",
doi = "10.1016/S1536-1632(01)00007-5",
language = "English (US)",
volume = "4",
pages = "119--127",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - The planning and design of a new PET radiochemistry facility

AU - Jacobson, Mark S.

AU - Hung, Joseph C.

AU - Mays, Trenton L.

AU - Mullan, Brian P.

PY - 2002

Y1 - 2002

N2 - The objectives of the Mayo positron emission tomography (PET) radiochemistry facility are the production of PET drugs for clinical service of our in-house patients, commercial distribution of PET drug products, and development of new PET drugs. The factors foremost in the planning and design phases were the current regulatory climate for PET drug production, radiation safety issues, and effective production flow. A medium-energy cyclotron was preferred for its small footprint to allow a compact vault, its high-proton energy to offer a higher product radioactivity; and its research capabilities. A vault installation was chosen instead of a self-shielded machine for improved access and ease of maintenance. Adjacent to the cyclotron is an area that houses the support equipment and a large dedicated workshop to support machine maintenance and targetry development. The total floor area of the PET radiochemistry facility is 344.2 m2 (3,705.5 ft2), of which the radiochemistry laboratory occupies 130.7 m2 (1,407 ft2). To reduce environmental contamination of PET drug products, the laboratory contains a controlled-air environment class 10,000 (M5.5) clean room with access via an interlocking entry change area. A fully shielded isolator (class 100 [M3.5]) is located in the clean room. The PET drugs are delivered via shielded tubing between the synthesizer and isolator. Inside the isolator, there is an automated device for dispensing the PET drug into either a bulk-activity vial or a unit-dose syringe. The dispensed PET radiopharmaceutical then passes through a hatch to a dedicated area where it is packaged for in-house use or commercial distribution. Unit doses for in-house patients are transported via pneumatic tube to the PET imaging area 76.2 m (250 ft) away. There is extensive radiation area monitoring throughout the facility that continuously measures radiation levels. We believe that our new PET radiochemistry facility not only meets overall objectives, but also provides an ergonomic, efficient working environment for the production and development of PET drugs.

AB - The objectives of the Mayo positron emission tomography (PET) radiochemistry facility are the production of PET drugs for clinical service of our in-house patients, commercial distribution of PET drug products, and development of new PET drugs. The factors foremost in the planning and design phases were the current regulatory climate for PET drug production, radiation safety issues, and effective production flow. A medium-energy cyclotron was preferred for its small footprint to allow a compact vault, its high-proton energy to offer a higher product radioactivity; and its research capabilities. A vault installation was chosen instead of a self-shielded machine for improved access and ease of maintenance. Adjacent to the cyclotron is an area that houses the support equipment and a large dedicated workshop to support machine maintenance and targetry development. The total floor area of the PET radiochemistry facility is 344.2 m2 (3,705.5 ft2), of which the radiochemistry laboratory occupies 130.7 m2 (1,407 ft2). To reduce environmental contamination of PET drug products, the laboratory contains a controlled-air environment class 10,000 (M5.5) clean room with access via an interlocking entry change area. A fully shielded isolator (class 100 [M3.5]) is located in the clean room. The PET drugs are delivered via shielded tubing between the synthesizer and isolator. Inside the isolator, there is an automated device for dispensing the PET drug into either a bulk-activity vial or a unit-dose syringe. The dispensed PET radiopharmaceutical then passes through a hatch to a dedicated area where it is packaged for in-house use or commercial distribution. Unit doses for in-house patients are transported via pneumatic tube to the PET imaging area 76.2 m (250 ft) away. There is extensive radiation area monitoring throughout the facility that continuously measures radiation levels. We believe that our new PET radiochemistry facility not only meets overall objectives, but also provides an ergonomic, efficient working environment for the production and development of PET drugs.

KW - Controlled environment

KW - Cyclotron

KW - FDA guidelines

KW - Hot cells

KW - Isolator

KW - Positron emission tomography PET

KW - Production flow

KW - Radiation safety

KW - Self-shielded

KW - Vault

UR - http://www.scopus.com/inward/record.url?scp=0036203710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036203710&partnerID=8YFLogxK

U2 - 10.1016/S1536-1632(01)00007-5

DO - 10.1016/S1536-1632(01)00007-5

M3 - Article

VL - 4

SP - 119

EP - 127

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 2

ER -